ANVISA granted landmark approval for polylaminin-based therapy for spinal cord injury in April 2026, offering ! Swipe to see →
On April 21, 2026, Brazil's National Health Surveillance Agency (ANVISA) announced the approval of polylaminin-based therapy for the trea...
Polylaminin is a biopolymer derived from laminin-111, a naturally occurring protein found in the extracellular matrix (ECM) — the complex...
The first human trials began in 2019 at HC-FMUSP with 28 patients who had chronic incomplete spinal cord injuries. The primary endpoint w...
ANVISA's approval was granted under its "Innovative Therapy" pathway, a regulatory framework created in 2023 specifically to accelerate t...
The ANVISA approval immediately attracted international attention. The US Food and Drug Administration (FDA) reportedly reached out to th...
Brazil records approximately 11,000 new spinal cord injuries per year, primarily from traffic accidents (42%), falls (27%), and violence ...
Visit our portal and read the full story!